` RNA (Avidity Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

RNA
vs
S&P 500

Over the past 12 months, RNA has underperformed S&P 500, delivering a return of -26% compared to the S&P 500's +13% growth.

Stocks Performance
RNA vs S&P 500

Loading
RNA
S&P 500
Add Stock

Performance Gap
RNA vs S&P 500

Loading
RNA
S&P 500
Difference
www.alphaspread.com

Performance By Year
RNA vs S&P 500

Loading
RNA
S&P 500
Add Stock

Competitors Performance
Avidity Biosciences Inc vs Peers

S&P 500
RNA
ABBV
AMGN
GILD
VRTX
Add Stock

Avidity Biosciences Inc
Glance View

Market Cap
4.1B USD
Industry
Biotechnology

Avidity Biosciences Inc. is a biopharmaceutical company on the cutting edge of science devoted to treating severe diseases through breakthrough technology. Founded in 2012, Avidity's primary innovation lies in its pioneering platform known as the Antibody Oligonucleotide Conjugates (AOCs). This inventive approach merges the precision-targeting abilities of monoclonal antibodies with the potent gene-modulating capabilities of oligonucleotides. By effectively leveraging these two technologies, Avidity aims to address previously undruggable genetic conditions, providing new therapeutic avenues for diseases such as muscular dystrophies and other serious genetic disorders. The company channels its efforts into discovering, developing, and ultimately bringing these transformative therapies to market. The economic lifeline of Avidity Biosciences is deeply intertwined with its robust research and development pipeline, strategically focused partnerships, and potential revenue streams emanating from successful clinical trials. By innovating within the realm of RNA therapeutics, Avidity taps into collaborations with major pharmaceutical entities, further bolstering its financial standing. For instance, its collaborations often entail upfront technology access fees and potential milestone payments as drug candidates progress through clinical stages. Avidity's long-term financial model rests on the successful commercialization of its unique AOCs. Through these multifaceted operations, the company aims to generate sustainable revenue while making significant impacts in precision medicine, exemplifying a model that merges groundbreaking science with strategic industry alliances.

RNA Intrinsic Value
22.76 USD
Overvaluation 33%
Intrinsic Value
Price
Back to Top